• linkedin
  • Increase Font
  • Sharebar

    Researchers zero in on a cure for the common cold

    A hot toddy and some chicken noodle soup may have been the way to fight a cold in the past, but researchers at Emory University are on a path that may lead to a vaccine against the common cold.

    Researchers at Emory University are investigating a vaccine that combines dozens of varieties of rhinovirus to stimulate viral antibodies. It’s working in mice and monkeys, according to the study, titled “A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques,” published in Nature Communications.

    “A vaccine for rhinovirus is doable, though we have a lot of work ahead of us before it could be put into practice,” Martin Moore, PhD, associate professor and director of research in the division of pediatric infectious diseases at the Emory University School of Medicine, told Medical Economics.

    Rhinoviruses are the top cause of the common cold—more so than other viruses that can also cause colds—but it’s also more than that. According to a study in The Journal of Infectious Diseases, up to 80% of common cold illnesses are associated with rhinovirus, as well as 60% to 70% of asthma exacerbations in school-aged children. Rhinovirus infection also contributes to a number of other clinically significant progressions, including ear infections and respiratory complications.

    Moore said a vaccine for rhinovirus could reduce asthma and chronic obstructive pulmonary disorder (COPD) exacerbations, as well as colds and acute cough.

    Next: Old research yields new clues

    Rachael Zimlich, RN
    Ms Zimlich is a freelance writer in Cleveland, Ohio. She writes regularly for Contemporary Pediatrics, Managed Healthcare Executive, and ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow